Program
Folic Acid
Also written as “Norgestimate; Ethinyl Estradiol; Folic acid”, “Vitamin B12, Vitamin B6, Folic acid” and “Amlodipine besylate and folic acid”.
Its studies are mostly in Hypertension · Arthritis, Rheumatoid · Vitamin B 12 Deficiency · Hypophosphatasia · Essential Hypertension, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Ausa Pharmed | 52 open or running | phase 4since Nov 19, 2008 | Nov 19, 2008 | Jun 30, 2029phase 4 · NCT04974151 |
| Johnson & Johnson | 30 open or running | phase 1since Jun 30, 2008 | Jun 30, 2008 | none ahead |
| AstraZeneca | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| Celltrion | 10 open or running | phase 1since May 22, 2013 | May 22, 2013 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2008First studies: 3 phase 1 studiesNew to Johnson & JohnsonJohnson & Johnson · NCT00709982, NCT00709332, NCT00709267
- Nov 19, 2008Shenzhen Ausa Pharmed's first study: phase 4 study in Essential HypertensionNew to Shenzhen Ausa PharmedShenzhen Ausa Pharmed · NCT00794885 · 20,702 enrolled · China
- May 22, 2013Celltrion's first study: phase 1 study in Arthritis, RheumatoidNew to CelltrionCelltrion · NCT01873443 · 87 enrolled · Korea, Republic of
- May 29, 2013Phase 4 study in HypertensionShenzhen Ausa Pharmed · NCT01871740 · China
- Mar 14, 2018Phase 4 study in HypertensionShenzhen Ausa Pharmed · NCT03472508 · 3,600 enrolled · China
- Jul 13, 20212 phase 4 studies in HypertensionShenzhen Ausa Pharmed · NCT04974151, NCT04974138
- Aug 23, 2023AstraZeneca's first study: phase 4 study in HypophosphatasiaNew to AstraZenecaAstraZeneca · NCT06015750
Ahead
- Jun 30, 2029Primary completion: phase 4 study in HypertensionShenzhen Ausa Pharmed · NCT04974151
- Jun 30, 2030Primary completion: phase 4 study in HypertensionShenzhen Ausa Pharmed · NCT04974138
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06015750Hypophosphatasia | 4 | Withdrawn | AstraZeneca | Mar 13, 2030 | 0 |
| NCT04974151Hypertension · China | 4 | Recruiting | Shenzhen Ausa Pharmed | Jun 30, 2029 | 24,000 |
| NCT04974138Hypertension · China | 4 | Recruiting | Shenzhen Ausa Pharmed | Jun 30, 2030 | 32,000 |
| NCT03472508Hypertension · China | 4 | UNKNOWN | Shenzhen Ausa Pharmed | Mar 30, 2019 | 3,600 |
| NCT01871740Hypertension · China | 4 | Withdrawn | Shenzhen Ausa Pharmed | Jun 2014 | 0 |
| NCT01873443Arthritis, Rheumatoid · Korea, Republic of | 1 | Completed | Celltrion | Oct 2014 | 87 |
| NCT00794885Essential Hypertension · China | 4 | Completed | Shenzhen Ausa Pharmed | Aug 2013 | 20,702 |
| NCT00709982Drug Interactions | 1 | Completed | Johnson & Johnson | 47 | |
| NCT00709332Drug Interactions | 1 | Completed | Johnson & Johnson | 47 | |
| NCT00709267Healthy | 1 | Completed | Johnson & Johnson | 12 |
How it is read
Names in the registry
- “Folic Acid”, 2 entries
- “Norgestimate; Ethinyl Estradiol; Folic acid”, 2 entries
- “Vitamin B12, Vitamin B6, Folic acid”, 1 entry
- “Amlodipine besylate and folic acid”, 1 entry
- “Amlodipine besylate And Folic Acid”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, 4 studies
- Arthritis, Rheumatoid, 2 studies
- Vitamin B 12 Deficiency, 1 study
- Hypophosphatasia, 1 study
- Essential Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.